A phase II clinical study of using nab-paclitaxel as second-line chemotherapy for Chinese patients with advanced non-small cell lung cancer
Crossref DOI link: https://doi.org/10.1007/s12032-015-0498-x
Published Online: 2015-05-06
Published Print: 2015-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hu, Wei
Zhang, Zhiping
Text and Data Mining valid from 2015-05-06